The United Arab Emirates Develops the First Local AI-Based Drug Candidate

The **Emirates Drug Establishment** has announced the development of the first-ever drug candidate entirely designed in the Emirates using artificial intelligence technologies, marking a significant advancement in the field of medical innovation.

A Major Scientific Breakthrough
This project was led by **Insilico Medicine**, which utilized generative AI tools to create this new compound, illustrating a profound transformation in traditional pharmaceutical research methods.

A Promising Cancer Treatment
The candidate, named ISM0387, is an advanced inhibitor targeting specific mechanisms related to certain tumors. It shows high potential for treating cancers, particularly solid tumors and brain cancers, while minimizing the impact on healthy cells.

Accelerated Development Through AI
Thanks to artificial intelligence, the discovery phase was completed in just six months, compared to several years with conventional approaches, following the evaluation of dozens of candidate molecules.

A Strategic Cooperation for Innovation
This success is part of a partnership between Insilico Medicine and the Emirati drug authority, aimed at strengthening national capabilities in biotechnology and promoting a favorable ecosystem for innovation.

Promising Outlook for Healthcare
This advancement paves the way for more precise and effective treatments, while reinforcing the Emirates’ position as an emerging player in the technology-driven pharmaceutical industry and scientific research.